The scientists explained that this result might contribute to developing new strategies for fighting the most frequent type of cancer affecting women.
Two thirds of breast cancers are ERá positive, that is, many estrogen receptors of the ERá type are found in their cells. “These molecules can interact with the estrogen hormone and, thus, even lead to cancer,” explains Doctor Joerg Hoheisel; molecular biologist at DKFZ. “The connection between the levels of the estrogen receptor á and the occurrence of breast cancer has been known for some time now.
Early-stage breast cancer cells already produce too many of these receptors. This is associated with increased cell division, which is ultimately responsible for tumor development,” says Hoheisel.
Jointly with his coworkers, Doctor Yasser Riazalhosseini and Pedro de Souza Rocha Simonini, Joerg Hoheisel has now been able to show that a tiny little nucleic acid, a microRNA known as miR-375, causes the high receptor levels which, in many cases, lead to cancer. MicroRNAs are important intracellular signal mediators, which have a substantial influence on the effectiveness of genes.
The DKFZ group discovered that miR-375 blocks the production of an enzyme which influences the production of ERá receptors. Thus, high levels of miR-375 lead to production of many estrogen receptors. At the same time, elevated ERá levels lead to production of more miR-375. This feedback loop further boosts the multiplication of cancer cells.
The research group headed by Hoheisel has now published the results of their experiments in the journal Cancer Research. They also present a first indication of a possible medical application of the newly gained knowledge: “We were able to block the miR-375 microRNA in ERá positive breast cancer cells. This effectively slowed down cancer cell growth.” Whether and how miR-375 will play a role in breast cancer treatment in the future is a question which Hoheisel cannot answer yet. “But we hope to be able to use our results in the future for developing new strategies against tumors with too many estrogen receptors.”
MEDICA.de; Quelle: German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)